Table 2.
Univariate and multivariate Cox regression analysis for overall survival.
| Variable | Category | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | p Value | Adjusted HR (95% CI) | p Value | ||
| ECOG PS | 0 or 1 | 1 | 1 | ||
| 2 | 2.45 (1.72–3.47) | <0.001 | 2.23 (1.49–3.34) | <0.001 | |
| >3 | 5.30 (2.29–9.92) | <0.001 | 3.28 (1.58–6.79) | 0.001 | |
| CCI | 0 | 1 | 1 | ||
| 1 | 1.57 (1.14–2.17) | 0.006 | 1.20 (0.85–1.70) | 0.31 | |
| ≥2 | 1.87 (1.25–2.79) | 0.002 | 0.88 (0.54–1.43) | 0.61 | |
| AJCC stage | 3A | 1 | 1 | ||
| 3B | 1.67 (1.09–2.58) | 0.020 | 1.60 (1.02–2.50) | 0.040 | |
| 3C | 3.26 (2.15–4.94) | <0.001 | 2.36 (1.51–3.70) | <0.001 | |
| Body weight loss | <5% | 1 | 1 | ||
| ≥5% | 2.50 (1.84–3.41) | <0.001 | 1.75 (1.25–2.47) | 0.001 | |
| Vascular invasion | No | 1 | 1 | ||
| Yes | 1.70 (1.26–2.30) | 0.001 | 1.40 (1.00–1.97) | 0.050 | |
| Resection margin | Negative | 1 | 1 | ||
| Positive | 2.27 (1.50–3.43) | <0.001 | 1.44 (0.92–2.25) | 0.12 | |
| Operation method | TG | 1 | 1 | ||
| STG | 0.56 (0.44–0.79) | <0.001 | 1.60 (1.02–2.50) | 0.040 | |
| Adjuvant chemotherapy | No | 1 | |||
| yes | 0.47 (0.35–0.64) | <0.001 | 0.52 (0.38–0.72) | <0.001 | |
| GPS | 0 | 1 | |||
| 1 | 2.52 (1.80–3.52) | <0.001 | 1.97 (1.36–2.86) | <0.001 | |
| 2 | 2.26 (1.45–3.53) | <0.001 | 1.57 (0.96–2.57) | 0.07 | |
ECOG PS, Eastern Cooperative Oncology Group performance status; CCI, Charlson comorbidity index; AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; TG, total gastrectomy; STG, subtotal gastrectomy; HR, hazard ratio; CI, confidence interval; GPS, Glasgow prognostic score.